BHMT2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-10819
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the C terminal region of human BHMT2 (NP_001171476.1). Peptide sequence RYIGGCCGFEPYHIRAIAEELAPERGFLPPASEKHGSWGSGLDMHTKPWI
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
44 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for BHMT2 Antibody
Western Blot: BHMT2 Antibody [NBP3-10819]
Western Blot: BHMT2 Antibody [NBP3-10819] - Western blot analysis of BHMT2 in Human THP-1 Whole Cell lysates. Antibody dilution at 1ug/mlApplications for BHMT2 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: BHMT2
Alternate Names
betaine-homocysteine methyltransferase 2, betaine--homocysteine S-methyltransferase 2, EC 2.1.1.5, FLJ20001
Gene Symbol
BHMT2
Additional BHMT2 Products
Product Specific Notices for BHMT2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...